Learning Hub

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Key Facts keyfacts 1 Understanding Psoriatic Arthritis Learn what psoriatic arthritis is, how it’s connected to psoriasis, what symptoms to look out for, how it’s diagnosed, and how to recognise a flare. f1.1 f1.2 See related Handbook section See related Handbook section See related Handbook section See related Handbook section See related Handbook section f1.3 f1.5 F1.4 keyfacts 2 Managing Psoriatic Arthritis: Treatments and Lifestyle Learn how psoriatic arthritis is treated through medications, non-pharmacological treatments, and everyday lifestyle choices that support health and wellbeing. See related Handbook section See related Handbook section See related Handbook section See related Handbook section See related Handbook section f2.1 f2.2 f2.3 f2.4 f2.5 keyfacts 3 Living with Psoriatic Arthritis Everyday tips for balancing work, improving sleep, managing fatigue, and supporting mental wellbeing. f3.1 See related Handbook section See related Handbook section See related Handbook section See related Handbook section f3.2 f3.3 f3.4 key facts 4 Intimacy, Reproductive Health and Family Life Understanding how psoriatic arthritis may affect relationships, sexual and reproductive health, and family planning decisions. See related Handbook section See related Handbook section See related Handbook section See related Handbook section f4.1 f4.2 f4.3 f4.4

< BACK Exploring the iPROLEPSIS Project: Insights from J. Luime Sep 17, 2024 Innovative Approaches to Monitoring and Managing Psoriatic Arthritis Jolanda Luime, senior researcher and project partner from Erasmus MC (the Netherlands), shares insights on the iPROLEPSIS project. The iPROLEPSIS project represents a significant advancement in the field of psoriatic arthritis research. By leveraging cutting-edge technology, including smartphones and data analysis, iPROLEPSIS aims to transform how we measure and understand psoriatic arthritis activity. Traditional methods of tracking psoriatic arthritis often fall short in capturing the full scope of the disease’s impact. iPROLEPSIS seeks to address this gap by exploring new and innovative approaches. The project uses advanced technology to monitor movement patterns and other key indicators of disease activity, offering a more comprehensive view of how the condition affects patients on a daily basis. One of the core objectives of iPROLEPSIS is to empower patients with better tools for managing their condition. By providing more detailed insights into disease activity, the project aims to help patients make informed decisions about their health and potentially prevent disease flares before they occur. This proactive approach has the potential to significantly improve the quality of life for those living with psoriatic arthritis. In addition to benefiting patients, iPROLEPSIS aims to to support clinicians by offering more accurate and actionable data. With better insights into disease activity and treatment effectiveness, healthcare providers can make more informed decisions regarding medication adjustments and overall treatment strategies. This not only enhances patient care but also helps streamline clinical practices, making the process more efficient and effective. Through the iPROLEPSIS project, the aim is to provide patients and clinicians with the tools they need to better understand and manage psoriatic arthritis, ultimately improving both patient outcomes and clinical practices. https://www.youtube.com/watch?v=G2Gz-gl5uBY 1/1 PREVIOUS NEXT

< BACK The protocol for iPROLEPSIS-PDPID study approved in the Netherlands Nov 12, 2023 Ongoing preparation for iPROLEPSIS-PDPID study initiation In November 2023, the protocol for the PsA Digital Phenotyping and Inflammation Drivers Study (iPROLEPSIS-PDPID) received ethical approval In the Netherlands. Approvals in the UK, PT and GR are in progress. The research will be conducted in the Netherlands, the UK, Portugal and Greece. The primary objective of the iPROLEPSIS-PDPID is to establish a development cohort to create smartphone and smartwatch-based, AI-driven digital biomarkers for the remote assessment and monitoring of individuals with psoriatic arthritis. Two action types will occur in the development cohort: measure and predict. Measure: To develop novel smartphone and smart device digital biomarkers for the assessment of inflammatory symptoms with a particular focus on the recognition of changes in movement patterns, pain, fatigue, and morning stiffness in comparison to the gold standard – medical evaluation by clinical evaluation of the joints, tendons and skin. Predict: To predict the change from uninflamed to inflamed using three triggers that may cause longstanding inflammation in psoriatic arthritis patients at risk for flare. Those three triggers are stress, mechanical stress and changes in the gut microbiome. To achieve these objectives, iPROLEPSIS-PDPID will leverage cutting-edge technology and a comprehensive set of products, such as a mobile phone app and a smartwatch. The miPROLEPSIS phone app, which will be used in this study, is currently under development. The app will be installed on the patients’ smartphones and utilised as a data collector before being used to develop and train algorithms. mIPROLEPSIS app.png mIPROLEPSIS app.png 1/1 PREVIOUS NEXT

Dissemination and communication team Kristina Leipuviene SmartSol SIA Position Project manager What is your role in iPROLEPSIS? Dissemination/Communication lead What are your main activities in the project? Leading and planning communication and dissemination activities. SmartSol team also supports networking and clustering with stakeholders. What is your motivation? As leaders of WP6, SmartSol aims to increase awareness of iPROLEPSIS and make it accessible to everyone. We focus on sharing information, raising awareness about psoriatic arthritis, and making a lasting impact through thoughtful planning and engagement with the public. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

< BACK Ongoing preparation for the iPROLEPSIS-PDPID study Mar 4, 2024 iPROLEPSIS-PDPID Study: Advancing Psoriatic Arthritis through Innovative Digital Biomarkers Patients with Psoriatic arthritis (PsA) experience difficulties in dealing with unpredictable disease activity, which can affect their quality of life. Developing a digital biomarker using a smartphone and smartwatch would allow for unobtrusive monitoring of the disease activity in these patients. Besides, understanding what factors trigger flare would allow for better disease control. The iPROLEPSIS-PDPID study is a multicentre observational cohort study that aims to develop an unobtrusive and affordable digital biomarker capable of detecting changes in disease activity, including flare, and to identify triggers of flare in patients with PsA. The study will be conducted in four countries: the Netherlands, the UK, Portugal and Greece. Ethical approval for initiating the iPROLEPSIS-PDPID study in the Netherlands and the UK has been granted. The OpenClinica platform will be used in the collection and storage of data for the iPROLEPSIS-PDPID study. Future steps include obtaining ethical approvals for Portugal and Greece as well as local approvals from centres participating in each country, and inclusion of patients from each participating country. The miPROLEPSIS phone app , currently under development, will be used in this study. The app will be installed on the patient smartphone and utilised as a data collector, which will be then used for algorithms development and training. The app will measure physical activity, the length of sleep, self-registered flare, and register daily pain, fatigue, sleep and morning stiffness. The Garmin smartwatch Vivoactive 5 device will be used to collect data on physical activity, heart rate, heart rate variability and sleep quality. The collected data from Garmin will be downloaded from the miPROLEPSIS app by Wellics software (developer in the project), which allows extracting, visualising and exporting collected both company-processed data, as well as raw data. 10.png 13.png 14.png 10.png 1/5 PREVIOUS NEXT

< BACK iPROLEPSIS Kick-Off Meeting Jan 8, 2023 iPROLEPSIS, a four-year Horizon Europe project on AI-enabled Psoriatic Arthritis screening, monitoring, and care, kicked off. iPROLEPSIS, a four-year H orizon Europe project on AI-enabled Psoriatic Arthritis screening, monitoring, and care, kicked off. Our consortium partners met in Thessaloniki, Greece, and during a two-day event laid the groundwork for this exciting research and innovation venture. The focus was placed on the four clinical studies that will be conducted in the project. News & Events iPROLEPSIS.png News & Events iPROLEPSIS.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS 3rd Plenary Meeting Nov 30, 2023 iPROLEPSIS 3rd Plenary Meeting in Rotterdam: 12-13 December 2023 On 12-13 December 2023, iPROLEPSIS partners will meet in Rotterdam for the third plenary meeting. The agenda includes workshops on the PDPID study, digital biomarkers, technical ecosystem development, serious games co-creation, an External Advisory Board session, and more. Stay tuned for updates on our progress! iPROLEPSIS 3rd Plenary meeting (1).png iPROLEPSIS 3rd Plenary meeting (1).png 1/1 PREVIOUS NEXT

< BACK World Psoriasis Day 2025: Advancing Prevention and Care Oct 29, 2025 On World Psoriasis Day, iPROLEPSIS highlights ongoing efforts to improve early detection, prevention, and digital support for people living with psoriasis and psoriatic arthritis October 29 marks World Psoriasis Day – a day dedicated to raising awareness of the impact psoriasis has on millions worldwide. For many, the condition goes beyond the skin: up to 30% develop psoriatic arthritis , an inflammatory disease that causes joint pain, stiffness, and fatigue, significantly affecting daily life. This year’s World Psoriasis Day video shares how iPROLEPSIS is working to advance psoriatic arthritis prevention and care. Through clinical studies, digital biomarkers, and co-created digital health tools, the project aims to support early detection , timely monitoring , and personalised care . The ongoing PDPID study is developing and validating predictive models for psoriatic arthritis progression, while the iPROLEPSIS digital ecosystem – including the miPROLEPSIS apps, miDashboard for professionals, and lifestyle interventions – is designed together with patients and clinicians to make technology more supportive of everyday care. Its tools – the miPROLEPSIS and miPROLEPSIS-Lite apps, the miDashboard for professionals, and lifestyle interventions such as serious games and personalised recommendations – are co-created with patients and healthcare providers to ensure they are practical, easy to use, and truly supportive of everyday care. On this World Psoriasis Day, iPROLEPSIS stands with everyone living with psoriasis and psoriatic arthritis. Together with clinical and research partners across Europe, the project continues to work toward earlier detection, prevention, and innovative digital solutions to improve lives. Watch the World Psoriasis Day 2025 video here: https://www.youtube.com/watch?v=FvbTCNH9vMY Screenshot 2025-10-29 083418.png Screenshot 2025-10-29 083418.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS at the 2nd Healthy Longevity Symposium Nov 21, 2024 Showcasing the Serious Game Suite for PsA at the Healthy Longevity Symposium The iPROLEPSIS project coordinator, Prof. Leontios Hadjileontiadis , presented the Serious Game Suite for Psoriatic arthritis patients at the 2nd Healthy Longevity Symposium , held by Khalifa University in Abu Dhabi on 21-22 November 2024. The symposium gathered leading experts to explore key topics related to longevity and aging, which is recognised as the root cause of many chronic diseases. The event focused on the latest advancements in aging mechanisms, genomic precision medicine, rejuvenation, and social health policies. Discussions highlighted the potential of AI, advanced technologies, and precision medicine to address the challenges of aging, slow age-related diseases, and improve overall well-being. By integrating cutting-edge research and technology, iPROLEPSIS is advancing innovative solutions aimed at improving the lives of people living with PsA. 1/2 PREVIOUS NEXT

< BACK Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers Oct 30, 2024 The qualitative study exploring the perspective of psoriatic arthritis (PsA) patients towards the digital biomarkers (dBMs) Latest research initiative under the iPROLEPSIS project: Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers Abstract Objectives The widespread adoption of wearables, for example, smartphones and smartwatches in the daily lives of the general population, allows passive monitoring of physiological and behavioural data in the real world. This qualitative study explores the perspective of psoriatic arthritis (PsA) patients towards these so-called digital biomarkers (dBMs). Methods As part of a Design Thinking approach, six focus groups were conducted involving 27 PsA patients. The semistructured topic guide included disease activity, coping strategies, care needs, and potential advantages and disadvantages of dBMs. Thematic analysis followed an abductive coding method. Results PsA daily permeates patients’ lives, both physically and mentally. Participants discussed how their lives are focused on minimising the impact of the disease on their daily routines. Their attempts to gain control over their disease highly depend on trial and error. Flare-ups are related to physiological as well as behavioural micro and macro changes. Understanding these changes could enable the detection of (early) flare. Participants elicited pros and cons of the use of dBMs, discussed their intended use and made practical remarks. This led to three main themes: ‘Perceived dBM opportunities’, ‘Mapping Disease activity’ and ‘Perceived dBM barriers and pitfalls’. Conclusion PsA patients are receptive to dBMs for tracking the disease symptoms. Disease activity is regarded multifaceted and thus, dBMs should include a broad range of features to truly reflect the disease activity status. Reducing the time of trial and error in learning to manage the disease is regarded beneficial. Establishing and maintaining the relationship with their attending physicians is a prerequisite, even if remote patient monitoring becomes an alternative for some physical hospital visits. Read the full publication in RMD Open: https://rmdopen.bmj.com/content/10/4/e004699 Digital biomarkers for psoriatic arthritis a qualitative focus groups study on patient-per .pdf Download PDF • 1.55MB 1/1 PREVIOUS NEXT

< BACK Understanding Enthesitis in Psoriatic Arthritis Oct 7, 2024 iPROLEPSIS presented in the 16th Panhellenic Conference of EPEMY Aristotle University of Thessaloniki presented iPROLEPSIS in the 16th Panhellenic Conference of EPEMY held in Ioannina, Greece, from 3-6 October 2024. The presentation addressed important topics related to nesting, the role of enthesitis in Psoriatic Arthritis and Axial Spondyloarthritis, and the most appropriate treatment approaches for enthesitis and digitalis. This conference focused on inflammatory and autoimmune rheumatic, gastrointestinal, and skin diseases, as well as osteoporosis and osteoarthritis. Individual sessions covered Covid-19, cancer, neurological syndromes, and co-morbidities. The event emphasised clinically applied treatments, with interactive, cross-company tutorials and presentations of research projects from domestic centers, which were awarded for their contributions. Read more about the conference here . 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Clinical Studies' Planning Feb 12, 2023 iPROLEPSIS team starts the planning of the four clinical studies that will be conducted in the project. iPROLEPSIS team starts the planning of the four clinical studies that will be conducted in the project. iPROLEPSIS plans to carry out: 1) a study to design novel digital biomarkers for PsA; 2) a study to investigate new opto-acoustics biomarkers and the role of mast cells in PsA; 3) a study to validate the potential of the novel digital biomarkers to screen for PsA in persons with psoriasis; and 4) a study to evaluate the effectiveness of the envisioned iPROLEPSIS digital care ecosystem in reducing flares of persons with PsA. Office Scene .jpg Office Scene .jpg 1/1 PREVIOUS NEXT